Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04767022
Other study ID # CSP-DS1001
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 25, 2020
Est. completion date August 31, 2024

Study information

Verified date April 2023
Source Genoss Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of Genoss® DCB by demonstrating non-inferiority in patients with in-stent restenosis (ISR) compared with a product of the same category (Sequent® Please NEO). The experimental group was treated with Genoss® DCB, and the control group was treated with SeQuent® Please NEO. In this study, the end point of 9 months after procedure was used as the main endpoint to evaluate the efficacy of Paclitaxel coated PTCA balloon catheter. The safety of the catheter was evaluated by cardiovascular adverse events.


Description:

In a randomized controlled trials to compare with the same-category medical device (Sequent® Please NEO), 224 patients with in-stent restenosis (ISR) were recruited from a total of 13 institutions, and the enrolled subjects were 1: 1 through randomization. The ratio was assigned to the test group(Genoss® DCB) and the control group(SeQuent® Please NEO), and each of the test or control devices was assigned to receive the procedure. All patients were followed up 30 days, 6 months, 9 months, 1 year and 2 years after procedure, and angiographic follow-up was performed 9 months after procedure.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 224
Est. completion date August 31, 2024
Est. primary completion date December 20, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: Subject related inclusion criteria - Age=18 years old & =80 years old. - Patients with stable angina pectoris, unstable angina pectoris, stable acute myocardial infarction or confirmed silent myocardial ischemia. - Patients who can understand the purpose of the study and voluntarily participate in and sign informed consent. - It is suitable for patients undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). Desease related inclusion criteria - The target lesions were in stent restenosis: Mehran type I, II and III stenosis. - The stenosis rate of target lesion diameter was more than 70%, or more than 50%, accompanied by objective evidence of ischemia (such as stress electrocardiogram, myocardial perfusion imaging, FFR, etc.) - The reference vessel diameter of the target lesion was 2.0-4.0 mm, and the target lesion length was less than or equal to 26 mm. - It is expected that no more than two drug balloons will be used in each subject, and each target lesion can be covered by one drug balloon. - At most 2 primary lesions need interventional treatment, and the distance from the target lesion is more than or equal to 10 mm, and can be successfully treated before the intervention of the target lesion. Exclusion Criteria: Subject related exclusion criteria - A woman who is pregnant, lactating, or planning a pregnancy. - Patients with cardiogenic shock, acute infection, known bleeding or coagulation disorder, or history of cerebral hemorrhage, subarachnoid hemorrhage, active peptic ulcer and gastrointestinal bleeding within 3 months before operation. - Patients who are known to be allergic to aspirin, clopidogrel, ticagrelor, heparin, contrast agent, paclitaxel, or have contraindications to aspirin, clopidogrel or ticagrelor. - Patients with acute myocardial infarction within 1 week before operation. - Patients with Takayasu arteritis. - Left ventricular ejection fraction = 30%. - Acute or chronic renal insufficiency (serum creatinine > 2.0mg/dl or 178 µ mol / L). - Patients with life expectancy less than 1 year. - Patients participating in clinical trials of other drugs or medical devices. - According to the researcher's judgment, the patient's clinical condition is not suitable for this study, or the patient is expected to be unable to complete the follow-up study according to the protocol. Disease related exclusion criteria - The target lesion was total occlusion (Mehran type IV). - The target and non target lesions were left main artery lesions. - The target lesions were ostial, pontine and bifurcated lesions with branch diameter = 2.5mm. - Three vessel disease requiring treatment. - More than 3 lesions (including target lesions and non target lesions) need to be treated in target vessels. - ISR lesions intervened within 6 months before operation. - Angiography confirmed thrombus in the target vessel. - The target vessel is severely calcified, tortuous and angulated, so it is expected that the drug balloon catheter will not pass successfully. - The lesions that could not be pre dilated successfully were grade C or above dissection after pre dilation, or residual stenosis > 30%, or TIMI blood flow < grade III.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Paclitaxel Coated PTCA Balloon Catheter(Genoss® DCB)
Drug Coated Balloon
Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)
Drug Coated Balloon

Locations

Country Name City State
China Department of Cardiology, First Affiliated Hospital of Air Force Medical University of Chinese PLA Xi'an Shaanxi

Sponsors (1)

Lead Sponsor Collaborator
Genoss Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary In-segment late lumen loss after percutaneous coronary intervention in patients with ISR In-segment late lumen loss between test group(Genoss DCB) and control group(Sequent Please) evaluated by quantitiative coronary analysis in patients with ISR Follow-up angiography at 9 months after procedure
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A